AFP and hepatocellular carcinoma: For advanced HCC patients under nonsurgical oral sorafenib treatment, MRI imaging diagnosis combined with the criterion of AFP >400 ng/ml provides an objective indicator for HCC diagnosis and therapeutic assessment.